JB Pharma Q4 Results: Net profit jumps 43% YoY to Rs 126 crore

JB Pharma on Friday reported a 43% year-on-year (YoY) jump in net profit to Rs 126 crore for the January-March quarter of FY24. The drug maker had reported a net profit of Rs 88 crore in the year-ago period.

Revenue for the quarter rose 13% YoY to Rs 862 crore.

The Mumbai-based company reported operating earnings before interest, taxes, depreciation and amortisation (EBITDA) at Rs 210 crore, up from Rs 181 crore in the year-ago period.


The operating EBITDA margin improved 60 basis points YoY to 24.4%.

For the full year FY24, the revenue grew 11% YoY to Rs. 3484 crore and the EBITDA margin expanded 330 basis points to 27%.

Domestic formulations business reported 22% YoY growth to Rs 465 crore in Q4 FY24 led by recently added ophthalmology portfolio.

International business grew 4% at Rs 397 crore.

Contract development manufacturing organisation (CDMO) business crossed Rs 100 crore revenue in Q4FY24 for the first time.

“With strong focus on our leading brands, we continue to drive higher than market volume growth and gain share in our core therapeutic areas. The Ophthalmology portfolio has seen a smooth transition in Jan’24 and the business has started to gain momentum," said Nikhil Chopra, CEO and wholetime director, JB Pharma.

"The focus on improving business mix and cost management strategies has helped international business improve overall operating margins despite increase in freight costs on account of geo-political issues," Chopra added.